Division of Health Care Finance
Landon State Office Building
900 SW Jackson, Suite 900 N
Topeka, KS 66612-1220

Kansas Department of Health and Environment

Phone: 785-296-3981
Fax: 785-296-4813
www.kdheks.gov

Janet Stanek, Secretary

Laura Kelly, Governor

Drug Utilization Review Board Meeting
Agenda, Open Session July 20, 2022
10:00 a.m. – 2:00 p.m.

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:

Computer Audio Enabled Zoom Meeting: **https://us02web.zoom.us/j/89410932015**

Required Passcode: 537369 Audio Dial in: (312) 626-6799, Meeting ID: 894 1093 2015

Members of the general public are required to complete a conflict-of-interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (July 13, 2022). Please email the completed form to Annette.Grant@ks.gov.

Board Members

Moneeshindra Mittal, MD (Chair)
James Backes, PharmD
Gregory Burger, PharmD, CPPS, FASHP, EMT
Daryl J. Callahan, D.O., M.S.S.
Cori Durall, PharmD
Jennifer Clair, MD
Kristen Powell, PharmD
Michele Reisinger, DNP, APRN, FNP-BC
Arthur Snow, MD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD
Sridevi Donepudi, MD
Carol Arace, Administrative Specialist

Gainwell Technologies/KEPRO Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN
Christina Faulkner, PharmD, BCPS
Harry Vu, PharmD

MCO Staff

Mark DeMary, PharmD, **Aetna Better Health of Kansas**
Angie Yoo, PharmD, **Sunflower State Health Plan**
Sunny Bounyalath, PharmD, **UnitedHealthcare Community Plan**

I. CALL TO ORDER

A. Announcements

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of April 20, 2022 Meeting Minutes

III. NEW BUSINESS

A. Revised Prior Authorization (PA) Criteria

1. **Atopic Dermatitis (AD) Agents**
   This revision includes updates to the dosing of Dupixent and to step therapy.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Chimeric Antigen Receptor T-Cell (CAR-T) Agents**
   This revision adds Carvykti™ and provides updates to indications, dosing limits and/or diagnoses for Kymriah®, Tecartus®, Breyanzi® and Yescarta®.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Crohn's Disease Agents**
   This revision adds Skyrizi®, removes biosimilar agents that are not yet available on the market, and adds another reference for Therapeutic Drug Monitoring.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

4. **Ulcerative Colitis Agents**
   This revision adds Rinvoq®, removes biosimilar agents that are not yet available on the market, and adds another reference for Therapeutic Drug Monitoring.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

5. **Growth Hormone Agents (Somatropin Products)**
   This revision adds Skytrofa™, consolidates the initial and renewal criteria, and updates the criteria to the standard format.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

6. **Minimum Requirements Prior Authorization**
   This revision adds Demser® capsules.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

7. **Oncology - Auxiliary Agents**
   This revision adds Releuko®.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

8. **High Cost Compounds**
   This revision clarifies the prior authorization criteria.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

9. **Opioid Use Discussion – Long-Term Care Setting**
   Discussion on opioid use for pain management in Long-Term Care settings.
   i. *Public Comment
   ii. Board Discussion

B. Tentative Agenda Items (MHMAC and PDL Meeting Agenda Items)

1. **MHMAC Meeting (July 19, 2022) – Revised PA Criteria**

   a. ADHD Medications – Safe Use for All Ages
   -Addition of the adult dosage of Qelbree®.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **PDL Meeting (July 19, 2022) – New PDL Classes**

   a. Imiquimod: Aldara®, Zyclara®
   i. Public Comment
   ii. Board Discussion

   b. Prenatal Vitamins: Various Products
   i. Public Comment
   ii. Board Discussion

   c. Thyroid Hormones: Levoxyl®, Synthroid ®, Tirosint ®, Unithroid ®, Thyquidity™
   i. Public Comment
   ii. Board Discussion

C. Miscellaneous Items

1. **Fee-for-Service Retrospective Drug Utilization Review Outcomes Report**
   Outcomes data for the R-DUR interventions performed during SFY 2021 will be presented.
   i. Presentation
   ii. Board Discussion

2. **Fee-for-Service Retrospective Drug Utilization Review Topic Selections**
   The DUR Board will select topics for the two (2) FFS RDUR interventions between August and September 2022.
   i. Presentation
   ii. Board Discussion

3. **Retrospective Drug Utilization Review**
   Discussion about R-DUR effectiveness (impact on provider education/patient outcomes) and possible new strategies.
   i. Presentation
   ii. Board Discussion

IV. ADJOURN

The next DUR Board meeting is scheduled for October 19, 2022.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****